for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GenMark Diagnostics, Inc

GNMK.OQ

Latest Trade

24.04USD

Change

0.03(+0.12%)

Volume

235,189

Today's Range

24.01

 - 

24.05

52 Week Range

7.81

 - 

24.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
24.01
Open
24.02
Volume
235,189
3M AVG Volume
61.66
Today's High
24.05
Today's Low
24.01
52 Week High
24.25
52 Week Low
7.81
Shares Out (MIL)
73.60
Market Cap (MIL)
1,767.02
Forward P/E
-202.96
Dividend (Yield %)
--

Next Event

Q1 2021 Genmark Diagnostics Inc Earnings Release

Latest Developments

更多

GenMark Diagnostics Reports Fourth Quarter And Full Year 2020 Results

Genmark Diagnostics Sees FY 2020 Revenue About $171 Million

Genmark Diagnostics Reports Qtrly Net Loss Per Share, Basic And Diluted $0.05

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GenMark Diagnostics, Inc

GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.

Industry

Medical Equipment & Supplies

Contact Info

5964 La Place Ct

CARLSBAD, CA

92008-8829

United States

+1.760.4484300

https://www.genmarkdx.com/

Executive Leadership

Kevin C. O'Boyle

Independent Chairman of the Board

Scott Mendel

President, Chief Executive Officer, Director

Johnny Ek

Chief Financial Officer

Eric Stier

Senior Vice President, General Counsel, Secretary

Michael Harkins

Senior Vice President - Sales

Key Stats

3.00 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.2K

2021(E)

0.2K
EPS (USD)

2018

-0.910

2019

-0.820

2020

-0.280

2021(E)

-0.118
Price To Earnings (TTM)
--
Price To Sales (TTM)
10.30
Price To Book (MRQ)
18.34
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
75.69
LT Debt To Equity (MRQ)
75.69
Return on Investment (TTM)
-13.99
Return on Equity (TTM)
-11.13

Latest News

Latest News

UPDATE 1-U.S. lab products provider Avantor to buy Germany's Ritter for $1.1 bln

U.S. laboratory products supplier Avantor has agreed to buy German peer Ritter for 890 million euros ($1.1 billion) in cash, adding to a wave of dealmaking in the sector.

UPDATE 2-DiaSorin strikes $1.8 bln Luminex deal to dodge 'COVID cliff'

Italian diagnostics firm DiaSorin has agreed to buy U.S. rival Luminex Corp for $1.8 billion in a move that could boost its molecular business and offset a potential drop in demand for COVID-19 tests as the pandemic is brought under control.

UPDATE 2-European shares flat as financials, miners weigh; Flutter rises

* Flutter lifts travel and leisure stocks (Adds comments, updates prices throughout)

European shares rise, Danone jumps after CEO ouster

European stocks rose on Monday on gains in French food company Danone and Swiss drugmaker Roche Holding, with optimism about a strong economic rebound calming concerns about quickening inflation.

FACTBOX-U.S. pours billions into securing access to coronavirus vaccine candidates

As drugmakers race to develop vaccines and therapies for the novel coronavirus, the United States is rushing to secure access to them. The U.S. government has agreed to invest more than $7 billion in vaccines and has funded more than 30 projects, including for diagnostics...

BRIEF-Genmark Diagnostics Reports First Quarter 2018 Results

* Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up